Boswell, Sarah A.

Machine learning identifies candidates for drug repurposing in Alzheimer’s disease

Rodriguez, S., Hug, C., Todorov, P., Moret, N., Boswell, S. A., Evans, K., Zhou, G., Johnson, N. T., Hyman, B. T., Sorger, P. K., et al. (2021) · Nature Communications

Computational Drug Discovery MethodsAlzheimer's disease research and treatments

Cited by 299

Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity

Hafner, M., Mills, C. E., Subramanian, K., Chen, C., Chung, M., Boswell, S. A., Everley, R. A., Liu, C., Walmsley, C. S., Juric, D., et al. (2019) · Cell Chemical Biology

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 250

Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.

Schauer, N. J., Liu, X., Magin, R. S., Doherty, L. M., Chan, W. C., Ficarro, S. B., Hu, W., Roberts, R. M., Iacob, R. E., Stolte, B., et al. (2020) · Scientific Reports

Ubiquitin and proteasome pathwaysCancer-related Molecular Pathways

Cited by 125

Silencing SMOC2 ameliorates kidney fibrosis by inhibiting fibroblast to myofibroblast transformation

Gerarduzzi, C., Kumar, R. K., Trivedi, P., Ajay, A. K., Iyer, A., Boswell, S., Hutchinson, J. N., Waikar, S. S., & Vaidya, V. S. (2017) · JCI Insight

Chronic Kidney Disease and DiabetesConnective Tissue Growth Factor Research

Cited by 79